ArticleOncology letters2018

Gastrointestinal perforation during treatment with erlotinib plus bevacizumab in two patients with non-small cell lung cancer exhibiting epidermal growth factor receptor mutations: A case report.

Teppei Yamaguchi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.